RT Journal Article
SR Electronic
T1 Combined treatment of nightmares with targeted memory reactivation and imagery rehearsal therapy: a randomized controlled trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.17.22270256
DO 10.1101/2022.02.17.22270256
A1 Schwartz, Sophie
A1 Clerget, Alice
A1 Perogamvros, Lampros
YR 2022
UL http://medrxiv.org/content/early/2022/02/19/2022.02.17.22270256.abstract
AB Background Nightmare disorder (ND) is characterized by dreams with strong negative emotions occurring during rapid-eye movement (REM) sleep. ND is mainly treated by imagery rehearsal therapy (IRT), where the patients are asked to change the negative story line of their nightmare to a more positive one.Methods We used targeted memory reactivation (TMR) during REM sleep to strengthen IRT-related memories and accelerate remission of ND. Thirty-six patients (27 women) with ND were asked to perform an initial IRT session and, while they generated a positive outcome of their recurrent nightmare, half of the patients were exposed to a sound (TMR group), while no such pairing with a sound took place for the other half (control group). During the next two weeks, all patients performed IRT every evening at home, and were exposed to the sound during REM sleep with a wireless headband, which automatically detected sleep stages. The frequency of nightmares per week at 2 weeks and at a three-month follow-up was used as primary outcome measure.Results We found that the patients of the TMR group had less frequent nightmares (p=.026, Cohen’s d=1.05) and more positive dream emotions (p=.004, Cohen’s d=1.06) than patients of the control group after two weeks of IRT, and a sustained decrease of nightmares after 3 months (p=.006, Cohen’s d=1.45).Conclusions By demonstrating the effectiveness of TMR during sleep to potentiate therapy, these results have clinical implications for the management of ND, with plausible relevance for learning-based therapies in other psychiatric diseases. Additionally, these findings show that TMR applied during REM sleep can modulate emotions in dreams.Clinical trial registration ClinicalTrials.gov identifier NCT05237778Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05237778Funding StatementThis study was supported by Swiss National Science Foundation, Grant/Award Number: CRSK-3_190722.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethical committee of Canton of Geneva, Switzerland (Commission Cantonale d'Ethique de la Recherche sur l'etre humain) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.